immunomodul induct phase lymphokine-activ killer activ acut phase protein effect treatment head neck cancer biolog respons modifi understand vivo factor capabl lymphokine-activ killer lak cell phenomenon eighteen patient squamou cell carcinoma head neck killer cell patient recombin u/ml complet medium complet medium autolog serum solut cytotox squamou cell carcinoma cell line use standard chromium-releas assay immunomodulatori capac serum level variou acut phase protein autolog serum induct phase lak phenomenon patient patient earli stage II diseas signific inhibit induct direct correl inhibit acut phase protein level invers relationship compon complement induct inhibit find advanc vivo immunomodulatori therapi elucid mechan serolog inhibit induct phase lak phenomenon such studi modif treatment efficaci biolog respons modifi 